162 related articles for article (PubMed ID: 37790973)
1. Lenalidomide improves NKG2D-based CAR-T cell activity against colorectal cancer cells invitro.
Zarei M; Abdoli S; Farazmandfar T; Shahbazi M
Heliyon; 2023 Oct; 9(10):e20460. PubMed ID: 37790973
[TBL] [Abstract][Full Text] [Related]
2. Antitumor activity of NKG2D CAR-T cells against human colorectal cancer cells in vitro and in vivo.
Deng X; Gao F; Li N; Li Q; Zhou Y; Yang T; Cai Z; Du P; Chen F; Cai J
Am J Cancer Res; 2019; 9(5):945-958. PubMed ID: 31218103
[TBL] [Abstract][Full Text] [Related]
3. Lenalidomide improves the antitumor activity of CAR-T cells directed toward the intracellular Wilms Tumor 1 antigen.
Zhang L; Jin G; Chen Z; Yu C; Li Y; Li Y; Chen J; Yu L
Hematology; 2021 Dec; 26(1):818-826. PubMed ID: 34674611
[TBL] [Abstract][Full Text] [Related]
4. Co-Expression of IL-7 Improves NKG2D-Based CAR T Cell Therapy on Prostate Cancer by Enhancing the Expansion and Inhibiting the Apoptosis and Exhaustion.
He C; Zhou Y; Li Z; Farooq MA; Ajmal I; Zhang H; Zhang L; Tao L; Yao J; Du B; Liu M; Jiang W
Cancers (Basel); 2020 Jul; 12(7):. PubMed ID: 32698361
[TBL] [Abstract][Full Text] [Related]
5. Memory T Cells Expressing an NKG2D-CAR Efficiently Target Osteosarcoma Cells.
Fernández L; Metais JY; Escudero A; Vela M; Valentín J; Vallcorba I; Leivas A; Torres J; Valeri A; Patiño-García A; Martínez J; Leung W; Pérez-Martínez A
Clin Cancer Res; 2017 Oct; 23(19):5824-5835. PubMed ID: 28659311
[No Abstract] [Full Text] [Related]
6. Suppression of 4.1R enhances the potency of NKG2D-CAR T cells against pancreatic carcinoma via activating ERK signaling pathway.
Gao Y; Lin H; Guo D; Cheng S; Zhou Y; Zhang L; Yao J; Farooq MA; Ajmal I; Duan Y; He C; Tao L; Wu S; Liu M; Jiang W
Oncogenesis; 2021 Sep; 10(9):62. PubMed ID: 34548478
[TBL] [Abstract][Full Text] [Related]
7. DAP10 integration in CAR-T cells enhances the killing of heterogeneous tumors by harnessing endogenous NKG2D.
Li S; Zhao R; Zheng D; Qin L; Cui Y; Li Y; Jiang Z; Zhong M; Shi J; Li M; Wang X; Tang Z; Wu Q; Long Y; Hu D; Wang S; Yao Y; Liu S; Yang LH; Zhang Z; Tang Q; Liu P; Li Y; Li P
Mol Ther Oncolytics; 2022 Sep; 26():15-26. PubMed ID: 35784403
[TBL] [Abstract][Full Text] [Related]
8. Combination therapy of DKK1 inhibition and NKG2D chimeric antigen receptor T cells for the treatment of gastric cancer.
Zhang Y; Liang K; Zhou X; Zhang X; Xu H; Dai H; Song X; Yang X; Liu B; Shi T; Wei J
Cancer Sci; 2023 Jul; 114(7):2798-2809. PubMed ID: 37151176
[TBL] [Abstract][Full Text] [Related]
9. Development of NKG2D-based chimeric antigen receptor-T cells for gastric cancer treatment.
Tao K; He M; Tao F; Xu G; Ye M; Zheng Y; Li Y
Cancer Chemother Pharmacol; 2018 Nov; 82(5):815-827. PubMed ID: 30132099
[TBL] [Abstract][Full Text] [Related]
10. Eradication of Hepatocellular Carcinoma by NKG2D-Based CAR-T Cells.
Sun B; Yang D; Dai H; Liu X; Jia R; Cui X; Li W; Cai C; Xu J; Zhao X
Cancer Immunol Res; 2019 Nov; 7(11):1813-1823. PubMed ID: 31484657
[TBL] [Abstract][Full Text] [Related]
11. Lenalidomide overcomes the resistance to third-generation CD19-CAR-T cell therapy in preclinical models of diffuse large B-cell lymphoma.
Jin Z; Xiang R; Qing K; Li D; Liu Z; Li X; Zhu H; Zhang Y; Wang L; Xue K; Liu H; Xu Z; Wang Y; Li J
Cell Oncol (Dordr); 2023 Aug; 46(4):1143-1157. PubMed ID: 37219767
[TBL] [Abstract][Full Text] [Related]
12. T cells expressing NKG2D chimeric antigen receptors efficiently eliminate glioblastoma and cancer stem cells.
Yang D; Sun B; Dai H; Li W; Shi L; Zhang P; Li S; Zhao X
J Immunother Cancer; 2019 Jul; 7(1):171. PubMed ID: 31288857
[TBL] [Abstract][Full Text] [Related]
13. Control of triple-negative breast cancer using ex vivo self-enriched, costimulated NKG2D CAR T cells.
Han Y; Xie W; Song DG; Powell DJ
J Hematol Oncol; 2018 Jul; 11(1):92. PubMed ID: 29980239
[TBL] [Abstract][Full Text] [Related]
14. Lenalidomide Enhances CAR-T Cell Activity Against Solid Tumor Cells.
Wang Z; Zhou G; Risu N; Fu J; Zou Y; Tang J; Li L; Liu H; Liu Q; Zhu X
Cell Transplant; 2020; 29():963689720920825. PubMed ID: 32967454
[TBL] [Abstract][Full Text] [Related]
15. Manufacturing development and clinical production of NKG2D chimeric antigen receptor-expressing T cells for autologous adoptive cell therapy.
Murad JM; Baumeister SH; Werner L; Daley H; Trébéden-Negre H; Reder J; Sentman CL; Gilham D; Lehmann F; Snykers S; Sentman ML; Wade T; Schmucker A; Fanger MW; Dranoff G; Ritz J; Nikiforow S
Cytotherapy; 2018 Jul; 20(7):952-963. PubMed ID: 30180944
[TBL] [Abstract][Full Text] [Related]
16. Electroporation of NKG2D RNA CAR Improves Vγ9Vδ2 T Cell Responses against Human Solid Tumor Xenografts.
Ang WX; Ng YY; Xiao L; Chen C; Li Z; Chi Z; Tay JC; Tan WK; Zeng J; Toh HC; Wang S
Mol Ther Oncolytics; 2020 Jun; 17():421-430. PubMed ID: 32462079
[TBL] [Abstract][Full Text] [Related]
17. Novel cellular immunotherapy using NKG2D CAR-T for the treatment of cervical cancer.
Zhang Y; Li X; Zhang J; Mao L
Biomed Pharmacother; 2020 Nov; 131():110562. PubMed ID: 32920508
[TBL] [Abstract][Full Text] [Related]
18. Annihilation of Non-small Cell Lung Cancer by NKG2D CAR-T Cells Produced from T Cells from Peripheral Blood of Healthy Donors.
Jiang J; Liu Y; Zeng Y; Fang B; Chen Y
J Interferon Cytokine Res; 2023 Oct; 43(10):445-454. PubMed ID: 37819621
[TBL] [Abstract][Full Text] [Related]
19. NK Cells Expressing a Chimeric Activating Receptor Eliminate MDSCs and Rescue Impaired CAR-T Cell Activity against Solid Tumors.
Parihar R; Rivas C; Huynh M; Omer B; Lapteva N; Metelitsa LS; Gottschalk SM; Rooney CM
Cancer Immunol Res; 2019 Mar; 7(3):363-375. PubMed ID: 30651290
[TBL] [Abstract][Full Text] [Related]
20. Adoptive Transfer of NKG2D CAR mRNA-Engineered Natural Killer Cells in Colorectal Cancer Patients.
Xiao L; Cen D; Gan H; Sun Y; Huang N; Xiong H; Jin Q; Su L; Liu X; Wang K; Yan G; Dong T; Wu S; Zhou P; Zhang J; Liang W; Ren J; Teng Y; Chen C; Xu XH
Mol Ther; 2019 Jun; 27(6):1114-1125. PubMed ID: 30962163
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
